These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 31178490)

  • 1. Vonoprazan versus Lansoprazole for the Initial Treatment of Reflux Esophagitis: A Cost-effectiveness Analysis in Japan.
    Habu Y
    Intern Med; 2019 Sep; 58(17):2427-2433. PubMed ID: 31178490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, in Patients with Proton Pump Inhibitor-Refractory Acid Reflux.
    Akiyama J; Hosaka H; Kuribayashi S; Moriyasu S; Hisada Y; Okubo H; Watanabe K; Imbe K; Nagata N; Kojima Y; Yokoi C; Uemura N; Shimoyama Y; Kawamura O; Yamada M; Kusano M
    Digestion; 2020; 101(2):174-183. PubMed ID: 30897577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment strategies for reflux esophagitis including a potassium-competitive acid blocker: A cost-effectiveness analysis in Japan.
    Habu Y; Hamasaki R; Maruo M; Nakagawa T; Aono Y; Hachimine D
    J Gen Fam Med; 2021 Sep; 22(5):237-245. PubMed ID: 34484992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis.
    Ashida K; Sakurai Y; Nishimura A; Kudou K; Hiramatsu N; Umegaki E; Iwakiri K; Chiba T
    Aliment Pharmacol Ther; 2015 Sep; 42(6):685-95. PubMed ID: 26201312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease.
    Gotoh Y; Ishibashi E; Honda S; Nakaya T; Noguchi C; Kagawa K; Murakami K
    Medicine (Baltimore); 2020 Mar; 99(11):e19520. PubMed ID: 32176102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility analysis of a 'vonoprazan-first' strategy versus 'esomeprazole- or rabeprazole-first' strategy in GERD.
    Yokoya Y; Igarashi A; Uda A; Deguchi H; Takeuchi T; Higuchi K
    J Gastroenterol; 2019 Dec; 54(12):1083-1095. PubMed ID: 31396703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Strategy for Standard-Dose Proton Pump Inhibitor-Resistant Reflux Esophagitis.
    Iwakiri K
    J Nippon Med Sch; 2017; 84(5):209-214. PubMed ID: 29142181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcomes of patients with symptomatic gastroesophageal reflux disease treated with vonoprazan.
    Shinozaki S; Osawa H; Kobayashi Y; Sakamoto H; Hayashi Y; Miura Y; Kawarai Lefor A; Yamamoto H
    Scand J Gastroenterol; 2018 Aug; 53(8):897-904. PubMed ID: 30056768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors Associated with Potassium-Competitive Acid Blocker Non-Response in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease.
    Okuyama M; Nakahara K; Iwakura N; Hasegawa T; Oyama M; Inoue A; Ishizu H; Satoh H; Fujiwara Y
    Digestion; 2017; 95(4):281-287. PubMed ID: 28501868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Utility Analysis of CYP2C19 Genotype Detection for Selection of Acid-Suppressive Therapy with Lansoprazole or Vonoprazan for Patients with Reflux Esophagitis in China.
    Zhang Z; Bao Y; Cai L; Gu Y; Yang T; Li X
    Clin Drug Investig; 2022 Oct; 42(10):839-851. PubMed ID: 35994227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of vonoprazan versus proton pump inhibitors in the treatment of reflux esophagitis in China.
    Wang Z; Sun R; Sheng Y; Qu S; Dong L; Wu B
    Ann Transl Med; 2022 Apr; 10(8):480. PubMed ID: 35571388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review.
    Miyazaki H; Igarashi A; Takeuchi T; Teng L; Uda A; Deguchi H; Higuchi K; Tango T
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1316-1328. PubMed ID: 30883868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis.
    Oshima T; Arai E; Taki M; Kondo T; Tomita T; Fukui H; Watari J; Miwa H
    Aliment Pharmacol Ther; 2019 Jan; 49(2):140-146. PubMed ID: 30589965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Efficacy of P-CAB vs Proton Pump Inhibitors for Grade C/D Esophagitis: A Systematic Review and Network Meta-analysis.
    Zhuang Q; Chen S; Zhou X; Jia X; Zhang M; Tan N; Chen F; Zhang Z; Hu J; Xiao Y
    Am J Gastroenterol; 2024 May; 119(5):803-813. PubMed ID: 38345252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.
    Ashida K; Iwakiri K; Hiramatsu N; Sakurai Y; Hori T; Kudou K; Nishimura A; Umegaki E
    World J Gastroenterol; 2018 Apr; 24(14):1550-1561. PubMed ID: 29662293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Vonoprazan for Proton Pump Inhibitor-Resistant Reflux Esophagitis.
    Hoshino S; Kawami N; Takenouchi N; Umezawa M; Hanada Y; Hoshikawa Y; Kawagoe T; Sano H; Hoshihara Y; Nomura T; Iwakiri K
    Digestion; 2017; 95(2):156-161. PubMed ID: 28190016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial.
    Laine L; DeVault K; Katz P; Mitev S; Lowe J; Hunt B; Spechler S
    Gastroenterology; 2023 Jan; 164(1):61-71. PubMed ID: 36228734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vonoprazan is superior to lansoprazole for healing of severe but not mild erosive esophagitis: A systematic review with meta-analysis of randomized controlled trials.
    Simadibrata DM; Lesmana E; Fass R
    J Gastroenterol Hepatol; 2024 Jun; 39(6):988-999. PubMed ID: 38353152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis.
    Xiao Y; Zhang S; Dai N; Fei G; Goh KL; Chun HJ; Sheu BS; Chong CF; Funao N; Zhou W; Chen M
    Gut; 2020 Feb; 69(2):224-230. PubMed ID: 31409606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021.
    Iwakiri K; Fujiwara Y; Manabe N; Ihara E; Kuribayashi S; Akiyama J; Kondo T; Yamashita H; Ishimura N; Kitasako Y; Iijima K; Koike T; Omura N; Nomura T; Kawamura O; Ohara S; Ozawa S; Kinoshita Y; Mochida S; Enomoto N; Shimosegawa T; Koike K
    J Gastroenterol; 2022 Apr; 57(4):267-285. PubMed ID: 35226174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.